Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease

医学 PCSK9 随机对照试验 安慰剂 内科学 他汀类 临床试验 胆固醇 脂蛋白 低密度脂蛋白受体 替代医学 病理
作者
Eric Klug,Sara Llerena,Lesley Burgess,Nyda Fourie,Russell Scott,Jeff Vest,Kate Caldwell,David Kallend,Evan A. Stein,LIBERATE-HR Investigators
出处
期刊:JAMA Cardiology [American Medical Association]
卷期号:9 (9): 800-800 被引量:47
标识
DOI:10.1001/jamacardio.2024.1659
摘要

Importance: Recent changes in national and international lipid guidelines for reducing cardiovascular events recommend additional drugs, greater reductions, and lower targets for low-density lipoprotein cholesterol (LDL-C) if not attained with statins. The achievement of these targets with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has not yet been evaluated in a randomized clinical trial. Objective: To evaluate the 52-week safety and efficacy of lerodalcibep, a small anti-PCSK9-binding protein, in patients with cardiovascular disease (CVD) or who are at very high or high risk of CVD and requiring addition LDL-C-lowering treatment. Design, Setting, and Participants: This was a randomized, double-blind, placebo-controlled phase 3 trial. The trial was conducted at 66 clinics in 11 countries between April 23, 2021, and November 15, 2023. Individuals 18 years and older taking maximally tolerated statin therapy with LDL-C of 70 mg/dL or greater with CVD or 100 mg/dL or greater if at high risk of CVD were included. Interventions: Patients were randomized 2:1 to monthly 1.2-mL subcutaneous lerodalcibep, 300 mg, or placebo for 52 weeks. Main Outcomes and Measures: The safety analysis included all randomized patients. The co-primary efficacy end points were percent change from baseline in LDL-C at week 52 and the mean of weeks 50 and 52. Secondary efficacy outcomes included additional lipid apolipoprotein measures and achievement of guideline-recommended LDL-C targets. Results: Of 922 randomized participants (mean [range] age, 64.5 [27-87] years; 414 [44.9%] female; mean [SD] baseline LDL-C, 116.2 [43.5] mg/dL), 811 (88%) completed the trial. The mean (SE) placebo-adjusted reduction in LDL-C with lerodalcibep by modified intention-to-treat (mITT) analysis was 56.2% (2.2%) at week 52 and 62.7% (1.9%) for the mean of weeks 50 and 52; 49.7% (2.4%) and 55.3% (2.2%) by ITT with imputation using a washout model, and 60.3% (2.3%) and 65.9% (1.9%) by per-protocol analysis at week 52 and the mean of weeks 50 and 52, respectively (P < .001 for all). With lerodalcibep, 555 of 615 participants (90%) achieved both a reduction in LDL-C of 50% or greater and recommended LDL-C targets during the study. Treatment-emergent adverse events were similar between lerodalcibep and placebo, except for injection site reactions. These occurred in 42 of 613 participants receiving lerodalcibep (6.9%) compared to 1 of 307 receiving placebo (0.3%), were graded mild or moderate, and did not result in higher discontinuation of treatment, at 26 of 613 (4.2%) and 14 of 307 (4.6%), respectively. Sporadic in vitro antidrug antibodies were detected, which had no impact on free PCSK9 or LDL-C-lowering efficacy. Conclusions and Relevance: In this trial, lerodalcibep, a novel anti-PCSK9 small binding protein, dosed monthly and stable at ambient temperatures significantly reduced LDL-C in patients with CVD or at high risk of atherosclerotic cardiovascular disease with a safety profile similar to placebo. These results support long-term use of lerodalcibep in patients with CVD or at high risk of CVD who are unable to achieve adequate LDL-C reduction while receiving maximal tolerated statins alone. Trial Registration: ClinicalTrials.gov Identifier: NCT04806893.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
orixero的应助被科研通管家采纳,获得10
刚刚
Ava的应助被科研通管家采纳,获得10
刚刚
充电宝的应助被科研通管家采纳,获得10
1秒前
1秒前
田様的应助被科研通管家采纳,获得10
1秒前
艾格发布了新的文献求助10
1秒前
1秒前
Owen的应助被科研通管家采纳,获得10
1秒前
深情安青的应助被科研通管家采纳,获得10
1秒前
研友_VZG7GZ的应助被王晨采纳,获得10
1秒前
以钛的应助被科研通管家采纳,获得10
1秒前
传奇3的应助被科研通管家采纳,获得10
1秒前
大模型的应助被科研通管家采纳,获得10
2秒前
星辰大海的应助被科研通管家采纳,获得10
2秒前
共享精神的应助被科研通管家采纳,获得10
2秒前
这两天天气咋样完成签到,获得积分10
2秒前
秋风的应助被科研通管家采纳,获得10
2秒前
ding的应助被科研通管家采纳,获得10
2秒前
2秒前
2秒前
赘婿的应助被科研通管家采纳,获得10
2秒前
3秒前
在水一方的应助被徐礼杨采纳,获得10
3秒前
yy完成签到,获得积分10
3秒前
yl666发布了新的文献求助10
4秒前
4秒前
Humble发布了新的文献求助30
4秒前
刘泽楷发布了新的文献求助10
5秒前
5秒前
还我小小嘴完成签到,获得积分10
6秒前
6秒前
6秒前
啊九lili发布了新的文献求助10
6秒前
7秒前
8秒前
靓丽瓦驴完成签到,获得积分10
8秒前
9秒前
9秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188177
求助须知:如何正确求助?哪些是违规求助? 9575987
关于积分的说明 21844723
捐赠科研通 7785975
什么是DOI,文献DOI怎么找? 3435220
关于科研通互助平台的介绍 2559558
邀请新用户注册赠送积分活动 2482095